Want to see AUPH full AI Analyst Report?
AUPH Stock Chart & Stats
$15.35
<$0.01(0.07%)
At close: 4:00 PM EDT
$15.35
<$0.01(0.07%)
Day’s Range― - ―
52-Week Range$10.34 - $19.25
Previous CloseN/A
Volume414.45K
Average Volume (3M)1.66M
Market Cap
$1.99B
Enterprise Value$1.89K
Total Cash (Recent Filing)$443.12M
Total Debt (Recent Filing)$60.42M
Price to Earnings (P/E)6.5
Beta0.37
Next Earnings
Oct 29, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.37
Shares Outstanding133,051,160
10 Day Avg. Volume901,393
30 Day Avg. Volume1,656,012
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.69
Price to Sales (P/S)7.57
P/FCF Ratio15.83
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$16.00Price Target Upside4.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.95
Revenue Forecast (FY)$331.35M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationOperating and free cash flow turned positive in 2024 and expanded through 2025 and TTM 2026, showing cash conversion closely tracking net income. Durable cash generation supports sustained R&D, commercialization, and M&A funding while reducing reliance on external financing if current revenue levels persist.
Improving Balance SheetLow debt relative to equity and improving leverage since 2023 provide financial flexibility. A stronger balance sheet enhances the company's ability to fund growth initiatives, absorb shocks, and invest in commercialization and pipeline development without immediate refinancing risk.
Strategic Pipeline ExpansionThe Kezar acquisition adds assets and programs that diversify Aurinia’s mostly single-product profile and expands long-term strategic options. Combined with initiated PRESERVE and combo trial activity, this strengthens the company’s clinical-stage pipeline and potential future revenue streams beyond core product sales.
Bears Say
Earnings/cash VolatilityA sharp earnings turnaround signals improvement but also highlights through-cycle volatility: deep losses as recently as 2021–2023 and unusually high recent margins raise concern that current profitability could reflect transient items or a narrow operating window, challenging predictability.
Single-product Revenue DependenceRevenue and cash flow remain heavily tied to one approved therapy. This concentration makes long-term results sensitive to prescription trends, payer reimbursement, competition, or label/regulatory changes, increasing operational risk until broader product diversification is realized.
Acquisition Integration RiskWhile the Kezar deal expands options, integration and execution risk can strain management focus, incur unexpected costs, and delay realization of pipeline synergies. These factors could pressure near-term margins and cash flow if integration is more complex or costly than planned.
Aurinia Pharmaceuticals News
AUPH FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was $10.34 and its highest was $19.25 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Aurinia Pharmaceuticals’s market cap is $1.99B.
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 77 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Aurinia Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.04.
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate is 0.22.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 133,051,160 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Aurinia Pharmaceuticals reported an EPS of $0.28 in its last earnings report, beating expectations of $0.24. Following the earnings report the stock price went up 6.188%.
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in AUPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurinia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (4.23% Upside)
$16.00 (4.23% Upside)
Blogger Sentiment
Bullish
AUPH Sentiment 75%
Sector Average 63%
Sector Average 63%
Insider Transactions
Bought Shares
Worth $12.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
57.64%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
AUPH Revenue Breakdown
90.00% U.S.
10.00% Japan
AUPH Stock 12 Month Forecast
Average Price Target
$16.00
▲(4.23% Upside)
Technical Analysis
Ownership Overview
13.26% Insiders
4.72% Mutual Funds
3.66% Other Institutional Investors
70.99% Public Companies and
Individual Investors